作者
Felipe Melo-González, Jorge A Soto, Liliana A González, Jorge Fernández, Luisa F Duarte, Bárbara M Schultz, Nicolás MS Gálvez, Gaspar A Pacheco, Mariana Ríos, Yaneisi Vázquez, Daniela Rivera-Pérez, Daniela Moreno-Tapia, Carolina Iturriaga, Omar P Vallejos, Roslye V Berríos-Rojas, Guillermo Hoppe-Elsholz, Marcela Urzúa, Nicole Bruneau, Rodrigo A Fasce, Judith Mora, Alba Grifoni, Alessandro Sette, Daniela Weiskopf, Gang Zeng, Weining Meng, José V González-Aramundiz, Pablo A González, Katia Abarca, Eugenio Ramírez, Alexis M Kalergis, Susan M Bueno
发表日期
2021/11/9
期刊
Frontiers in immunology
卷号
12
页码范围
747830
出版商
Frontiers Media SA
简介
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible of the current pandemic ongoing all around the world. Since its discovery in 2019, several circulating variants have emerged and some of them are associated with increased infections and death rate. Despite the genetic differences among these variants, vaccines approved for human use have shown a good immunogenic and protective response against them. In Chile, over 70% of the vaccinated population is immunized with CoronaVac, an inactivated SARS-CoV-2 vaccine. The immune response elicited by this vaccine has been described against the first SARS-CoV-2 strain isolated from Wuhan, China and the D614G strain (lineage B). To date, four SARS-CoV-2 variants of concern described have circulated worldwide. Here, we describe the neutralizing capacities of antibodies secreted by volunteers in the Chilean population immunized with CoronaVac against variants of concern Alpha (B.1.1.7), Beta (B.1.351) Gamma (P.1) and Delta (B.617.2).
Methods
Volunteers enrolled in a phase 3 clinical trial were vaccinated with two doses of CoronaVac in 0-14 or 0-28 immunization schedules. Sera samples were used to evaluate the capacity of antibodies induced by the vaccine to block the binding between Receptor Binding Domain (RBD) from variants of concern and the human ACE2 receptor by an in-house ELISA. Further, conventional microneutralization assays were used to test neutralization of SARS-CoV-2 infection. Moreover, interferon-γ-secreting T cells against Spike from variants of concern were evaluated in PBMCs from vaccinated …
学术搜索中的文章
F Melo-González, JA Soto, LA González, J Fernández… - Frontiers in immunology, 2021